
![]() |
|
research of Benefits
In our continuing efforts to document the strength and effectiveness of d-Lenolate, East Park Research retained one of the best research institutions in the United States. A series of studies were conducted on d-Lenolate's efficacy against some of the most serious bacterial and viral infections known. East Park is happy to
report that all three phases of this study have concluded with results that document d-Lenolate's direct anti-viral and anti-microbial activities. With these findings, East Park has begun the manufacturing process for a new d-Lenolate cream formulation. Once launched, the new cream formulation could become one of the most effective over-the-counter treatments for cold sores (HSV-I)..
Click Here to view the report
In 1854 “Pharmaceutical journal of Provincial Transactions,” doctors stated that the properties of the olive tree deserved more extensive investigation. In the early 1900’s, a bitter compounds was found in the leaves of certain olive trees, called “Oleuropein”. This compound was determined to be part of the olive tree’s powerful disease resistance structure. In 2000, clinical study conducted by Dr. Masatoshi Kaneko and his colleagues on the effects
of dietary supplement, d-Lenolate was investigated in terms of the restoration of leukocytopenia and the protection against E.coli, Pseudomonas aeruginosa and Candida albicans. The result indicated that d-Lenolate contributed to the enhancement and restoration of leukocyte levels to normal and provided protection against experimental infections.
Click Here to view the report In 2001, relationship between depressions of early protection against influenza virus infection
was also investigated using d-Lenolate with a positive result as published in the
Orthomolecular Organization website.
Click Here to view the report In conjunction with East Park’s continuing effort to document the strength and effectiveness
of d-Lenolate, in-vitro experiment of d-Lenolate against anthrax was conducted.
d-Lenolate demonstrated a dose-dependent inhibition against B.anthracis resulting
in a preliminary conclusion of antibacterial activity against anthrax.
|